BioSpectrum Asia: “Moving forward, cancer may not be a death threat but a manageable disease with strong control”
By Christine Filippis / November 6, 2024
Cartherics’ CEO, Prof. Alan Trounson was recently interviewed by BioSpectrum Asia discussing the development of the company’s cell-based immunotherapies for...
Read More
Cartherics is “Frocking Up” this month to support ovarian cancer research
By Christine Filippis / October 30, 2024
Cartherics is frocking up this October to raise funds and awareness for crucial ovarian cancer research. The current five-year survival...
Read More
Cartherics raises over $15 Million in oversubscribed private financing round to advance cell therapy programs
By Christine Filippis / October 1, 2024
Financing round was significantly oversubscribed by existing investors and new private investors. Funding will enable the Company to progress clinical...
Read More
Cartherics’ CEO named ScholarGPS highly ranked scholar for outstanding scholarly contributions
By Christine Filippis / September 20, 2024
We are pleased to announce that Cartherics’ CEO, Prof. Alan Trounson has been recognised as a ScholarGPS Highly Ranked Scholar...
Read More
Breakthrough FDA approval for first solid tumor cell therapy signals new era for cancer treatment
By Christine Filippis / August 8, 2024
Exciting advancements are on the horizon for cancer treatment. Earlier this year, the FDA approved Lifileucel, an autologous tumor infiltrating...
Read More
Cartherics enters agreements with UniQuest, The University of Queensland and The University of Sydney for advancing innovative cardiac cellular therapy
By Christine Filippis / July 25, 2024
Cartherics, UniQuest and The University of Sydney enter Technology Licence Agreement for Cartherics’ iPSC cell line. Cartherics, The University of...
Read More
Innovative Cancer Solutions: Cartherics’ Patented Immunotherapy Approach
By Christine Filippis / June 14, 2024
In a recent interview with Wholesale Investor, Cartherics’ COO, Dr Ian Nisbet shares deep insights into the company’s groundbreaking work...
Read More
Cartherics secures Australian patent for innovative cancer cell therapy
By Christine Filippis / June 12, 2024
Melbourne, Australia, 12 June 2024 – Cartherics Pty Ltd (“Cartherics” or “Company”), a biotechnology company developing immune cell therapies for...
Read More
Cartherics granted European patent for multiple development candidates
By Christine Filippis / May 23, 2024
Melbourne, Australia, 23 May 2024 – Cartherics Pty Ltd (“Cartherics” or “Company”), a biotechnology company developing immune cell therapies for...
Read More
Addressing solid tumours and the upcoming clinical trial of natural killer (NK) cell therapy for ovarian cancer
By Christine Filippis / May 22, 2024
Cartherics’ CEO, Prof. Alan Trounson AO recently presented at Private Capital 2024 held at the ASX Building in Sydney. During...
Read More
Cartherics: An Innovative Company Developing Cellular Immunotherapy Cancer Treatments
By Christine Filippis / May 14, 2024
Cartherics’ CEO, Prof. Alan Trounson was recently interviewed by Pulse 2.0 discussing Cartherics' innovative approach to using stem cells to...
Read More
The first baby from a frozen embryo turns 40!
By Christine Filippis / May 2, 2024
Cartherics’ CEO, Prof. Alan Trounson was recently interviewed by Barbara Barkhausen, a German speaking, Asia-Pacific Correspondent for a variety of...
Read More
Emergence of antibody-drug conjugates (ADCs) as the “hot, new technology” (and potential lessons for cell therapy companies)
By Christine Filippis / April 26, 2024
Ian Nisbet, PhD Chief Operating Officer, Cartherics Pty Ltd As published in pharmaphorum Background The recent acquisition of ImmunoGen by...
Read More
Cartherics enters into Collaborative Research Agreement with TiCARos
By Christine Filippis / April 2, 2024
Melbourne, Australia, 2 April 2024 – Cartherics Pty Ltd (“Cartherics”), a biotechnology company developing immune cell therapies for the...
Read More
Cartherics executes Option Agreement with The Ohio State University
By Christine Filippis / March 20, 2024
TISSUE FACTOR AS A NOVEL TARGET FOR CAR-NK CELLS Melbourne, Australia, 20 March 2024 – Cartherics Pty Ltd (“Cartherics” or...
Read More
